問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Surgery

Division of General Internal Medicine

Digestive System Department

Taipei Veterans General Hospital

更新時間：2023-09-19

陳仁熙Chen, Jen-Shi
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years

Recruiting Trial

82Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳仁熙

List

199Cases

2018-08-15 - 2020-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2009-10-31 - 2012-10-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2019-03-01 - 2020-06-30

Phase II

A Phase II Basket Study of the Oral Selective Pan-FGFR Inhibitor Debio 1347 in Subjects With Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3

  • Condition/Disease

    Solid Tumors

  • Test Drug

    Debio 1347

Participate Sites
7Sites

Terminated7Sites

2011-12-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2017-01-05 - 2019-12-31

Others

An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors

  • Condition/Disease

    Solid Tumors

  • Test Drug

    TECENTRIQ

Participate Sites
6Sites

Recruiting4Sites

Terminated1Sites

趙毅
Taipei Veterans General Hospital

陳仁熙
Linkou Chang Gung Medical Foundation

2019-10-01 - 2023-01-13

Phase II

A phase 2, multicenter open-label, non-randomized study of bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer who have progressed on or after at least one prior standard therapy

  • Condition/Disease

    Gastric Cancer / GastroEsophageal Cancer

  • Test Drug

    Bavituximab

Participate Sites
4Sites

Recruiting4Sites

2008-03-01 - 2011-12-03

Phase III

A Randomized , Multicenter, Open-label, Phase III Study of Lapatinib in Combination with weekly Paclitaxel versus weekly Paclitaxel alone in the second line treatment of ErbB2 amplified Advanced Gastric Cancer

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    Lapatinib

Participate Sites
6Sites

Terminated6Sites

2008-05-01 - 2012-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2015-12-01 - 2020-04-30

Phase III

A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF/ Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

  • Test Drug

    Pexastimogene Devacirepvec (Pexa Vec)

Participate Sites
6Sites

Terminated6Sites

2017-01-06 - 2022-01-05

Phase III

ONO-4538 Phase III Study A multicenter, double-blind, randomized study in patients with gastric cancer undergoing postoperative adjuvant chemotherapy

  • Condition/Disease

    Gastric Cancer

  • Test Drug

    Nivolumab

Participate Sites
10Sites

Terminated8Sites

白禮源
China Medical University Hospital-Taipei

未分科

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

1 12 13 14 15 16 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB